Surgo medical - Company finances
|
EUR
|
2022
From: 2022-11-03
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | - | 227,098 | 607,203 | 1,000,607 |
| Profit before tax | -59 | 47,174 | 133,521 | 203,164 |
| Net profit | -59 | 44,818 | 113,495 | 170,997 |
| Equity | 2,941 | 47,759 | 161,114 | 312,111 |
| Liabilities | 52 | 73,392 | 120,450 | 47,532 |
| Non-current assets | 0 | 9,339 | 38,505 | 31,569 |
| Current assets | 2,993 | 111,052 | 240,742 | 327,498 |
| Total assets | 2,993 | 120,391 | 279,247 | 359,067 |
|
Taxes paid
|
||||
| STI taxes | - | 37,613 | 89,134 | 182,446 |
| Social insurance contributions | - | - | 721 | 20,329 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | +167.4% | +64.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -2.0% | 37.2% | 40.6% | 47.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -2.0% | 93.8% | 70.4% | 54.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 19.7% | 18.7% | 17.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 20.8% | 22.0% | 20.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 1.5 | 0.7 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 170,328 | 220,801 | 279,242 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Surgo medical - Social security debts
The company had no debts to Sodra
Surgo medical - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-17 | 2026-04-20 | 0.16 |
| 2026-03-22 | 2026-03-22 | 0.16 |
| 2026-03-08 | 2026-03-17 | 92.73 |
| 2026-02-28 | 2026-03-07 | 4.2 |
| 2026-02-21 | 2026-02-21 | 140.63 |
| 2025-10-03 | 2025-10-03 | 13.25 |
| 2025-06-28 | 2025-07-20 | 16.29 |
| 2025-06-14 | 2025-06-16 | 1977.46 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Surgo medical, UAB (code 306171096) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company reported revenue of €1.00M and net profit of €171.0K, compared with €607.2K revenue and €113.5K net profit in 2024 and €227.1K revenue and €44.8K net profit in 2023. This shows strong growth over the 2023–2025 period, with revenue up 64.8% year on year in 2025 and 340.6% over two years. Profitability remained solid, although the net profit margin eased from 19.7% in 2023 to 18.7% in 2024 and 17.1% in 2025. The balance sheet also expanded, with total assets rising to €359.1K in 2025 from €279.2K in 2024 and €120.4K in 2023. Equity increased to €312.1K, while liabilities declined to €47.5K, indicating a stronger capital structure. Key ratios for 2025 were also strong, including ROE of 54.8%, ROA of 47.6%, debt-to-equity of 0.15, and asset turnover of 2.79x. Revenue per employee was €333.5K.